Pay in 4 interest-free payments of $7.05 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
A Phase 2 trial (NCT01311518) was designed to test RGN-352 in ~75 heart attack patients, but was placed on FDA clinical hold in 2011 due to manufacturing (GMP) compliance issues at the contract site not safety concerns with the drug itself
Frequency depends on the specific peptide
Consulting a healthcare provider allows for exploring potential treatments such as physical therapy
Low-quality or mislabeled products sold online can pose serious health risks
Many of our patients receive Hydroxocobalmin injections approximately once every 10 - 12 weeks
Buy Now Pay Later: Cherry, Klarna, Afterpay, CareCredit
US$ 28.52
US$ 24.25
US$ 23.53
US$ 27.06
US$ 25.77
US$ 22.91
US$ 20.06
US$ 23.61
